Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors

Gene Therapy

Volumn 10, Issue 21, 2003, Pages 1821-1829

  Bilbao, R ^a   Reay, D P ^a   Hughes, T ^a   Biermann, V ^b   Volpers, C ^b   Goldberg, L ^a   Bergelson, J ^c   Kochanek, S ^b   Clemens, P R ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

High capacity adenoviral vector; In utero; Muscle; RGD; Targeting

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; BETA3 INTEGRIN; MUSCLE PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL LINE; CONTROLLED STUDY; COXSACKIE VIRUS; DNA MODIFICATION; FETUS; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; IN VITRO STUDY; MOUSE; MUSCLE CELL; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADENOVIRIDAE; AMINO ACID MOTIFS; ANIMALS; BETA-GALACTOSIDASE; FEMALE; FETAL DISEASES; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; INTEGRINS; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; OLIGOPEPTIDES; PREGNANCY; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; DNA VIRUSES; MURINAE;

EID: 0141613885     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302084     Document Type: Article

References (39)

1. Jerebtsova M, Batshaw ML, Ye X. Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice. Pediatr Res 2002; 52: 95-104.
2. Mitchell M et al. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Therapy 2000; 7: 1986-1992.
3. Schneider H et al. Sustained delivery of therapeutic concentrations of human clotting factor IX-a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46-53.
4. Senoo M et al. Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction assay. Mol Genet Metab 2000; 69: 269-276.
5. Yang EY et al. Persistent postnatal transgene expression in both muscle and liver after fetal injection of recombinant adenovirus. J Pediatr Surg 1999; 34: 766-772.
6. Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999; 10: 2451-2459.
7. Bergelson JM et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
8. Bergelson JM et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
9. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
10. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257-264.
11. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-390.
12. Dechecchi MC et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
13. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1: 391-405.
14. Bouri K et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999; 10: 1633-1640.
15. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996; 2: 299-305.
16. Cao B et al. The role of receptors in the maturation-dependent adenoviral transduction of myofibers. Gene Therapy 2001; 8: 627-637.
17. Feero WG et al. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. Gene Therapy 1997; 4: 664-674.
18. Samoylova TI, Smith BF. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 1999; 22: 460-466.
19. Biermann V et al. Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757-1769.
20. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
21. Kasono K et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571-2579.
22. Vanderkwaak TJ et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 227-234.
23. Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
24. Mizuguchi H et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Therapy 2002; 9: 769-776.
25. Gullberg D, Velling T, Lohikangas L, Tiger CF. Integrins during muscle development and in muscular dystrophies. Front Biosci 1998; 3: D1039-D1050.
26. Hirsch E et al. Alpha v integrin subunit is predominantly located in nervous tissue and skeletal muscle during mouse development. Dev Dyn 1994; 201: 108-120.
27. Yamada S, Brown KE, Yamada KM. Differential mRNA regulation of integrin subunits alpha V, beta 1, beta 3, and beta 5 during mouse embryonic organogenesis. Cell Adhes Commun 1995; 3: 311-325.
28. Vizirianakis IS et al. Transfection of MCF-7 carcinoma cells with human integrin alpha7 cDNA promotes adhesion to laminin. Arch Biochem Biophys 2001; 385: 108-116.
29. Ontell M, Kozeka K. The organogenesis of murine striated muscle: a cytoarchitectural study. Am J Anat 1984; 171: 133-148.
30. Lewis MP et al. The extracellular matrix of muscle - implications for manipulation of the craniofacial musculature. Eur J Oral Sci 2001; 109: 209-221.
31. Huang S et al. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996; 70: 4502-4508.
32. Soudais C et al. Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 2000; 74: 10639-10649.
33. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 1995; 2: 107-115.
34. Borck C. The development of the myo-tendinous junction in the upper extremity of mouse embryos (days 15 p.c.-1 p.p.). Z Mikrosk Anat Forsch 1977; 91: 229-240.
35. Acsadi G et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 1994; 3: 579-584.
36. Stern C. Immunocytochemistry of embryonic material. In: Stern C, Holland P (eds). Essential Developmental Biology: A Practical Approach. Oxford University Press: New York, 1993, pp 193-212.
37. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.
38. Cohen CJ et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196.
39. Pan D et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 2002; 6: 19-29.